Abliva AB (FRA:NTP) Net Change in Cash : €-1.04 Mil (TTM As of Sep. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Abliva AB Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Abliva AB's Net Change in Cash for the three months ended in Sep. 2024 was €0.14 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2024 was €-1.04 Mil.

Abliva AB Net Change in Cash Historical Data

The historical data trend for Abliva AB's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abliva AB Net Change in Cash Chart

Abliva AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Change in Cash

Get a 7-Day Free Trial

3.09

0.33

-3.83

4.01

-0.78

Abliva AB Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Net Change in Cash	Get a 7-Day Free Trial															-0.43	-0.09	-2.34	1.25	0.14

Abliva AB Net Change in Cash Calculation

Abliva AB's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-0.697	+	-0.115	+	0.037	+	-0.004
	=	-0.78

Abliva AB's Net Change in Cash for the quarter that ended in Sep. 2024

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= -3.271 + -0.033 + 3.445 + -0.004

= 0.14

Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abliva AB Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Abliva AB's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Abliva AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abliva AB (FRA:NTP) » Definitions » Net Change in Cash

Comparable Companies

OSTO:ATORX XSAT:HAMLET B OSTO:BIOWKS OSTO:MAGLE OSTO:ACOU OSTO:KAN OSTO:ACTI OSTO:CLBIO OSTO:STABL OSTO:GUARD OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX

Traded in Other Exchanges

ABLI:Sweden 0QDU:UK

Address

Scheeletorget 1, Medicon Village, Lund, SWE, 223 81

Website

https://www.abliva.com

Abliva AB is a Swedish company that is active in pharmaceutical development. It develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare, and often very severe diseases occur when the cell's energy provider, the mitochondria, does not function properly. The portfolio includes projects at different stages and ranges from the early discovery phase to the clinical phase. . The company is focused on two projects. KL1333, a powerful NAD+ and NADH regulator, in late-stage development and has been granted orphan drug designation in Europe and the US. NV354, an energy replacement therapy, has just completed preclinical development.

Abliva AB Headlines

No Headlines